Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
34
resultados
Última actualización
13/01/2026 [07:18:00]
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: WO2026009791A1
Provided is a detection sensitivity-improving method for improving the sensitivity of detection of a protein. The detection sensitivity-improving method, which is used in a method for detecting, by an antigen-antibody reaction, a protein supported by a matrix, includes performing, before the antigen-antibody reaction, a boiling treatment in which the matrix on which the protein is supported is boiled in a sodium sulfate solution to thereby improve the sensitivity of detection of the protein by the antigen-antibody reaction. The protein is an etiological protein of dementia, such as Aβ and Tau. The method can also be applied to the improvement of the sensitivity of detection of a tag protein such as a His tag, an myc tag and a FLAG tag.
Resumen de: EP4675277A1
The present invention relates to a method for diagnosing or determining the risk of suffering from Alzheimer's disease in a subject, wherein the method comprises determining the level of at least the biomarkers Neurofilament light Chain (NfL), brain-derived neurotrophic factor (BDNF), and tumor growth factor beta 1 (TGF-beta 1) and in addition determining the level of one or more biomarkers selected from the group comprising interleukin 18 (IL-18), Monocyte chemotactic protein-1 (MCP-1), Insulin-like growth factor (IGF) and Vascular endothelial growth factor (VEGF) in a sample of bodily fluid of said subject, calculating a score from the determined biomarker levels, and comparing said score with a reference score, and wherein said subject is diagnosed with Alzheimer's disease, or said subject is determined as having a risk of suffering from Alzheimer's disease, if the score is above said reference score.
Resumen de: MX2025010930A
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: US2021132085A1
The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Aβ40), amyloid β42 (Aβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.
Resumen de: WO2026005695A1
The invention relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to human tau. The monoclonal antibody, or the antigen-binding fragment thereof, can be used in a homogenous immunoassay for the detection and quantification of oligomeric tau and soluble tau aggregates in body fluid samples.
Resumen de: US2025189536A1
The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.
Resumen de: WO2026006441A1
Some embodiments provide for a method for performing a multi-biomarker beta¬ amyloid status determining assay. The method may include: obtaining, for one or more blood or blood-derived samples, values for biomarkers associated with Alzheimer's disease, the values comprising a value for a phosphorylated Tau (p-Tau) and one or more values for one or more additional biomarkers; comparing the value for p-Tau to upper and lower thresholds to determine whether the value for p-Tau is greater than or equal to the lower threshold and less than or equal to the upper threshold; and after determining that the value for p-Tau is greater than or equal to the lower threshold and less than or equal to the upper threshold, further interrogating the intermediate range values that are indicative of borderline cases of amyloid pathology using a statistical model to obtain an output facilitating additional classification of the likelihood that the one or more blood or blood-derived samples are associated with a particular beta-amyloid status.
Resumen de: EP4671757A2
Provided herein is the use of a compound of Formula I:or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: EP4671765A1
The present disclosure discloses a method, system, composition, and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on spatial transcriptomics of a human hippocampus. In the present disclosure, the rapid and efficient early diagnosis and differential diagnosis of AD-associated cognitive impairment is achieved based on one or more of cholecystokinin (CCK), neurogranin (NRGN), and peripheral myelin protein 2 (PMP2) that are carried by plasma extracellular vesicles (EVs). The present disclosure enables the high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, and demonstrates advantages such as high efficiency and low cost. The present disclosure provides a new technical means and method for the clinical application and large-scale screening related to the accurate diagnosis of AD-associated cognitive impairment.
Resumen de: US2025389734A1
A method for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases, comprising determining the level of TPK1 protein in a sample from a subject, wherein a decrease in the level of TPK1 protein compared to a reference value indicates that the subject has Alzheimer's disease. Methods, compositions, test strips, test cards and/or kits for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases by detecting a biomarker, wherein the methods, compositions, test strips, test cards and/or kits can specifically diagnose Alzheimer's disease.
Resumen de: US2025388967A1
The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.
Resumen de: CN120660001A
A method of determining the extent of a central nervous system (CNS)-specific neurological disease in a subject includes collecting a sample of a biological fluid of the subject and measuring the amount of a first biomarker or a metabolite thereof or a corresponding mRNA in the sample by a dry spot or microfluidic device. The body fluid is blood capillary blood or saliva, and is suitable for on-site, hospital and family environments due to the advantage of convenient collection. The method has general practicability in the aspects of diagnosis, nursing and management of brain specific abnormal nerve diseases, and is particularly suitable for traumatic brain injury (TBI), Alzheimer's disease (AD) (induced by TBI) and Alexander disease (a disease of white matter deterioration caused by GFAP mutation).
Resumen de: CN120329431A
The present invention provides a method of measuring the amount of mono-or poly-phosphorylated p217 + tau protein in a sample. Also provided are methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of treatment of tauopathies, and methods of determining whether a subject is suitable for anti-p217 + tau antibody therapy. Antibodies for use in the methods and kits comprising the antibodies are also described.
Resumen de: WO2025258826A1
According to embodiments of the present disclosure, disclosed is a method for determining the possibility of Alzheimer's disease by using a brain organoid of a user, the method comprising the steps of: receiving, by a determination server, a first factor value measured by using a first method for a brain organoid cultured from a user's stem cells; determining whether the first factor value of the brain organoid exceeds a preset first reference value; if the first factor value exceeds the first reference value, determining that the user's possibility of developing slow-onset Alzheimer's disease is high; if the first factor value is less than or equal to the first reference value, obtaining a second factor value measured by applying a second method to the brain organoid of the user; and determining, on the basis of the second factor value, the user's possibility of developing rapid-onset Alzheimer's disease.
Resumen de: KR20250175781A
본 발명은 smp30의 알츠하이머병 치료 또는 수명 및 건강수명의 연장 용도에 관한 것이다. 본 발명에 따른 smp30은 알츠하이머병 질환 내 인산화된 타우 단백질의 감소 뿐만 아니라, 운동 능력 증가, 산화 스트레스에 대한 저항성 증가, 항산화 효과 증가, 굶주림 스트레스 저항성 증가 및 노화 감소에 대한 효과를 가져, 알츠하이머병 치료, 알츠하이머병 치료제 후보물질 발굴, 및 수명 및 건강수명 연장 또는 개선에 활용이 가능하다.
Resumen de: WO2025256506A1
Provided herein are plasma protein markers associated with neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD), diagnostic and treatment/management methods for these conditions, as well as kits for diagnosing and/or treating/monitoring these conditions. Machine learning systems and methods are also provided for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels.
Resumen de: WO2025260029A1
Disclosed herein are immunoassay methods of measuring amyloid β protofibril levels in biological samples and diagnostic and therapeutic uses thereof. Methods disclosed herein use a single molecule counting instrument for detection. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: WO2025259709A1
The present disclosure provides methods of screening for, identifying and using a Gi-GPCR agonist for a CNS disorder. The CNS disorder can be any disorder in which astrocyte morphology and/or astrocyte tissue support are altered or compromised (e.g., OCD, Alzheimer's disease, or Huntington's disease). Provided herein are methods of screening for and identifying Gi-GPCR agonist ex vivo based on assessment of astrocyte morphology and/or Gi-GPCR activation (e.g., wherein the Gi-GPCR is GPR3711, S1PR1, EDNRB, GRM3, or AD0RA2A). Also provided herein are methods of identifying a therapeutic agent for the treatment of a CNS disorder in vivo at least in part based on its effect on astrocyte morphology and/or Gi-GPCR activation. Also provided herein are methods for the treatment or prevention of a CNS disorder comprising administering to a subject a Gi-GPCR (e.g., GPR3711, S1PR1, EDNRB, GRM3, or AD0RA2A) agonist.
Resumen de: WO2024166074A1
The present invention relates to a method of isolating exosomes from human immature dental pulp stem cell (hIDPSC) cultures that is scalable. The present invention also provides pharmaceutical compositions comprising exosomes and methods of using these pharmaceutical compositions to treat a neurological disease or condition, infectious disease, or cancer.
Resumen de: EP4663754A2
The invention relates to a panel of biomarkers comprising tau or one or more fragments thereof.
Resumen de: AU2024274218A1
The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.
Resumen de: AU2024235526A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: US2025377367A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Nº publicación: US2025376508A1 11/12/2025
Solicitante:
THE US SECRETARY DEPT OF HEALTH AND HUMAN [US]
The United States of America, as represented by the Secretary, Dept. of Health and Human
Resumen de: US2025376508A1
The disclosure generally relates to immunoglobulin and/or antigen binding fragment(s) that specifically bind to post-synaptic density (PSD95) phosphorylated at threonine (19), at (serine 25), and/or at both threonine (19) and serine (25), as well as corresponding expression vectors and host cells, and methods of diagnosing and kit using such immunoglobulin and/or antigen binding fragment(s) that specifically bind to PSD95 phosphorylated at threonine (19), at serine (25), and/or at both threonine (19) and serine (25).
BOPI
Sede Electrónica
